Diagnosis and Therapy of Nonalcoholic Steatohepatitis

Gastroenterology

Volumn 134, Issue 6, 2008, Pages 1682-1698

  Torres, Dawn M ^a   Harrison, Stephen A ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; BETAINE; EXENDIN 4; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; RIMONABANT; ROSIGLITAZONE; SIMVASTATIN; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

ARTICLE; BODY MASS; CALORIC INTAKE; CELL PROTECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIAGNOSTIC ACCURACY; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EDEMA; EXERCISE; HEART DISEASE; HIGH RISK POPULATION; HUMAN; INSULIN RESISTANCE; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; METABOLIC SYNDROME X; MONOTHERAPY; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RADIODIAGNOSIS; SCORING SYSTEM; SCREENING TEST; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 42949154244     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.02.077     Document Type: Article

References (165)

1. C. Beymer K.V. Kowdley A.A. Larson Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery Arch Surg 138 2003 1240 1244
2. P.M. Gholam L. Flanebaum J.T. Machan Nonalcoholic fatty liver disease in severely obese subjects Am J Gastroenterol 102 2007 399 408
3. M. Machado P. Marques-Vidal H. Cortez-Pinto Hepatic histology in obese patients undergoing bariatric surgery J Hepatol 45 2006 600 606
4. L.A. Adams J.F. Lymp J.S. Sauver The natural history of nonalcoholic fatty liver Gastroenterology 129 2005 113 121
5. G. Targher L. Bertolini F. Poli Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients Diabetes 54 2005 3541 3546
6. M. Hamaguchi T. Kojima N. Takeda Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease World J Gastroenterol 13 2007 1579 1584
7. U. Arslan S. Turkoglu S. Balcioglu Association between nonalcoholic fatty liver disease and coronary artery disease Coron Artery Dis 18 2007 433 436
8. S. Liangpunsakul N. Chalasani Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol 37 2003 340 343
9. S.A. Harrison S. Torgerson P. Hayashi The natural history of nonalcoholic fatty liver disease: a clinical histopathological study Am J Gastroenterol 98 2003 2042 2047
10. I.R. Wanless J.S. Lentz Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors Hepatology 12 1990 1106 1110
11. S.A. Harrison B.A. Neuschwander-Tetri Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis Clin Liver Dis 8 2004 861 879
12. L.A. Adams S. Sanderson K.D. Lindor The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies J Hepatol 42 2005 132 138
13. M. Pantsari S.A. Harrison Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase J Clin Gastroenterol 40 2006 633 635
14. B. Palmentieri I. de Sio V. La Mura The role of bright liver echo pattern on ultrasound B-mod examination in the diagnosis of liver steatosis Dig Liver Dis 38 2006 485 489
15. M. Hamaguchi T. Kojima Y. Itoh The severity of ultrasound findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation Am J Gastroenterol 102 2007 1 8
16. C.C. Mottin M. Moretto A.V. Padoin The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients Obes Surg 14 2004 635 637
17. G. Celle V. Savarino A. Picciotto Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques Dig Dis Soc 33 1988 467 471
18. S. Saadeh Z.M. Younossi E.M. Remer The utility of radiological imaging in nonalcoholic fatty liver disease Gastroenterology 123 2002 745 750
19. S.H. Park P.N. Kim K.W. Kimg Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment Radiology 239 2006 105 112
20. D.G. Duman C. Celikel D. Tuney Computed tomography in nonalcoholic fatty liver disease: a useful tool for hepatosteatosis assessment? Dig Dis Sci 51 2006 346 351
21. S.W. Lee S.H. Park K.W. Kim Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index Radiology 244 2007 479 485
22. M.K. Fishbein K.G. Gardner C.J. Potter Introduction of fast MR imaging in the assessment of hepatic steatosis Magn Reson Imaging 15 1997 287 293
23. P. Charatcharoenwitthaya K.D. Lindor Role of radiologic modalities in the management of nonalcoholic steatohepatitis Clin Liver Dis 11 2007 37 54
24. L.S. Szczepaniak P. Nurenberg D. Leonard Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am J Physiol 288 2005 E462 E468
25. O. Cheung A. Kapoor P. Puri The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome Hepatology 46 2007 1091 1100
26. J.W. Haukeland Z. Konopski P. Linnestad Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease Scand J Gastroenterol 40 2005 1469 1477
27. B. Balkau New diagnostic criteria for diabetes and mortality in older adults DECODE study group, European Diabetes Epidemiology Group Lancet 353 1999 68 69
28. G. Marchesini E. Bugianesi G. Forlani Non-alcoholic steatohepatitis in patients cared in metabolic units Diabetes Res Clin Pract 63 2004 143 151
29. G. Marchesini E. Bugianesi G. Forlani Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome Hepatology 37 2003 917 923
30. S.M. Grundy J.L. Cleeman S.R. Daniels Diagnosis and management of the metabolic syndrome Circulation 112 2005 2735 2752
31. E.M. Brunt C.G. Janney A.M. DiBisceglie Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions Am J Gastroenterol 94 1999 2467 2474
32. D.E. Kleiner E.M. Brunt M. Van Natta Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
33. V. Ratziu E. Bugianesi J. Dixon Histological progression of non-alcoholic fatty disease: a critical reassessment based on liver sampling variability Aliment Pharmacol Ther 26 2007 821 830
34. H. Iijima F. Moriyasu K. Tsuchiya Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis Hepatol Res 37 2007 722 730
35. M. Yoneda K. Fujita M. Inamori Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD) Gut 56 2007 1330 1331
36. J.A. Talwalkar D.M. Kurtz S.J. Schoenleber Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis Clin Gastroenterol Hepatol 5 2007 1214 1220
37. M. Fraquelli C. Rigamonti G. Casazza Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease Gut 56 2007 968 973
38. M. Yin J.A. Talwalkar K.J. Glaser Assessment of hepatic fibrosis with magnetic reasonance elastography Clin Gastroenterol Hepatol 5 2007 1209 1213
39. A.J. Sanyal C. Campbell-Sargent F. Mirshahi Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities Gastroenterology 120 2001 1183 1192
40. N. Chalasani M.A. Deeg D.W. Crabb Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis Am J Gastroenterol 99 2004 1497 1502
41. D. Bonnefont-Rousselot V. Ratziu P. Giral Blood oxidative stress markers are unreliable makers of hepatic steatosis Aliment Pharmacol Ther 23 2006 91 98
42. E. Tsochatzis G.V. Papatheodororidis A.J. Archimandritis The evolving role of leptin and adiponectin in chronic liver diseases Am J Gastroenterol 101 2006 1 12
43. F.A. Anania S. Parekh Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease Gastroenterology 132 2007 2191 2207
44. A. Uygun A. Kadayifci Z. Yesilova Serum leptin levels in patients with nonalcoholic steatohepatitis Am J Gastroenterol 95 2000 3584 3589
45. S. Chitturi G. Farrell L. Forst Serum leptin in NASH correlates with hepatitis steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 36 2002 403 409
46. K. Nakao K. Nakata N. Ohtsubo Association between nonalcoholic fatty liver, markers of obesity, and serum leptin levels in young adults Am J Gastroenterol 97 2002 1796 1801
47. N. Chalasani D.W. Crabb O.W. Cummings Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 98 2003 2771 2776
48. J.M. Hui A. Hodge G.C. Farrell Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40 2004 46 54
49. G. Musso R. Gambino G. Biroli Hypoadiponectinemia predicted the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis Am J Gastroenterol 100 2005 2438 2446
50. E. Bugianesi U. Pagotto R. Manini Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin sensitivity and hepatic fat content of liver, not to liver disease severity J Clin Endocrinol Metab 90 2005 3498 3504
51. S. Kaser A. Moschen A. Canyon Adiponectin and its receptors in nonalcoholic steatohepatitis Gut 54 2005 117 121
52. M. Shimada H. Kawahara K. Ozaki Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis Am J Gastroenterol 102 2007 1931 1938
53. R. Vuppalanchi S. Marri D. Kolwankar Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study J Clin Gastroenterol 39 2005 237 242
54. G. Targher L. Bertolini S. Rodella Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease Clin Endocrinol 64 2006 679 683
55. J.M. Hui G.C. Farrell J.G. Kench High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD Hepatology 39 2004 1458 1459
56. M. Yoneda H. Mawatari K. Fujita High sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH J Gastroenterol 42 2007 573 582
57. G. Targher Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease J Hepatol 45 2006 879 882
58. A.E. Feldstein A. Canbay P. Angulo Hepatic apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis Gastroenterology 125 2003 437 443
59. A. Wieckowska N.N. Zein L.M. Yerian In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease Hepatology 44 2006 27 33
60. Y. Yilmaz E. Dolar E. Ulakaya Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis World J Gastroenterol 13 2007 837 844
61. R.R. Mitry R. De Bruyne A. Quaglia Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers Hepatology 46 2007 2047 2048
62. N.A. Palekar R. Naus S.P. Larson Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease Liver Int 26 2005 151 156
63. T. Poynard V. Ratziu F. Charlotte Diagnostic value of biochemical markers (NASHTest) for the prediction of nonalcohol steatohepatitis in patients with non-alcoholic fatty liver disease BMC Gastroenterol 6 2006 34
64. A. Wieckowska A.J. McCullough A.E. Feldstein Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future Hepatology 46 2007 582 589
65. V. Ratziu P. Giral F. Charlotte Liver fibrosis in overweight patients Gastroenterology 118 2000 1117 1123
66. V. Ratziu J. Massard F. Charlotte Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease BMC Gastroenterol 6 2006 6
67. W.M. Rosenberg M. Voelker R. Thiel Serum markers detect the presence of liver fibrosis: a cohort study Gastroenterology 127 2004 1704 1713
68. P. Angulo J.M. Hui G. Marchesini The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD Hepatology 45 2007 846 854
69. H. Kang J. Omo G. Joel Validation of the NAFLD fibrosis score in predicting advanced fibrosis in patients with histologically proven non-alcoholic fatty liver disease Hepatology 46 2007 750A
70. I.N. Guha J. Parkes P.R. Roderick Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease Gut 55 2006 1650 1660
71. E. Capristo L. Miele A. Forgione Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH) Eur Rev Med Pharmacol Sci 9 2005 265 268
72. F. Sato Y. Tamura H. Watada Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects J Clin Endocrinol Metab 92 2006 3326 3329
73. M. Palmer F. Schaffner Effect of weight reduction on hepatic abnormalities in overweight patients Gastroenterology 99 1990 1408 1413
74. T. Anderson C. Gluud M.B. Franzmann Hepatic effects of dietary weight loss in morbidly obese subjects J Hepatol 12 1991 224 229
75. M. Okita M. Hayashi T. Sasagawa Effect of moderately energy-restricted diet on obese patients with fatty liver Nutrition 17 2001 542 547
76. E.L. Thomas A.E. Brynes G. Hamilton Effect of nutritional counseling on hepatic, muscle, and adipose fat tissue content and distribution in non-alcoholic fatty liver disease World J Gastroenterol 12 2006 5813 5819
77. D.A. De Luis R. Aller O. Izaola Effect of a hypocaloric diet in transaminases in nonalcoholic fatty liver disease and obese patients, relation with insulin resistance Diabetes Res Clin Pract 79 2008 74 78
78. F.H. Luychkx C. Desaive A. Thiry Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty Int J Obes Relat Metab Disord 22 1998 222 226
79. J.G. Kral S.N. Thung S. Biron Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis Surgery 135 2004 48 58
80. J.S. Fisler E.J. Drenick Starvation and semistarvation diets in the management of obesity Ann Rev Nutr 7 1987 465 484
81. S.R. de Almeida P.R. Rocha M.D. Sanches Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity Obes Surg 16 2006 270 278
82. J.B. Dixon P.S. Bhathal P.E. O'Brien Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement Obes Surg 16 2006 1278 1286
83. K.B. Barker N.A. Palekar S.P. Bowers Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery Am J Gastroenterol 101 2006 368 373
84. J.M. Clark A.R. Alkhuraishi S.F. Solga Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease Obes Res 13 2005 1180 1186
85. M.A. Huang J.K. Greenson C. Chao One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study Am J Gastroenterol 100 2005 1072 1081
86. R.T. Wang R.L. Koretz H.F. Yee Is weight reduction an effective therapy for nonalcoholic fatty liver disease? A systematic review Am J Med 115 2003 554 559
87. G. Musso R. Gambino F. De Michieli Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis Hepatology 37 2003 909 916
88. K. Toshimitsu B. Matsuura I. Ohkubo Dietary habits and nutrient intake in non-alcoholic steatohepatitis Nutrition 23 2007 46 52
89. W.S. Yancy M.K. Olsen J.R. Guyton A low-carbohydrate, ketogenic diet versus a low fat diet to treat obesity and hyperlipidemia Ann Intern Med 140 2004 769 777
90. D. Tendler S. Lin W.S. Yancy The effect of low carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study Dig Dis Sci 52 2007 589 593
91. J. Westerback K. Lammi A. Hakkienen Dietary fat content modifies liver fat in overweight nondiabetic subjects J Clin Endocrinol Metab 90 2005 2804 2809
92. K.F. Petersen S. Dufour D. Befroy Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes Diabetes 54 2005 603 608
93. A.M. Zivkovic J.B. German A.J. Sanyal Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease Am J Clin Nutr 86 2007 282 300
94. A.M. El-Badry W. Moritz C. Contaldo Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids Hepatology 45 2007 841 845
95. D. Wang Y. Wei M.J. Pagliassotti Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis Endocrine 147 2006 943 951
96. J.A. Paniagua G. de la Sancristana I. Romero Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin resistant subjects Diabetes Care 30 2007 1717 1723
97. De. Laaksonen K. Nyyssonen L. Niskanen Prediction of cardiovascular mortality in middle-aged men by dietary and serum linoleic and polyunsaturated fatty acids Arch Intern Med 165 2005 193 199
98. M. Sekiya N. Yahagi T. Matsuzaka Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression Hepatology 38 2003 1529 1539
99. H. Cortez-Pinto L. Jesus H. Barros How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 25 2006 816 823
100. M. Capanni F. Calella Biagini Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study Aliment Pharmacol Ther 23 2006 1143 1151
101. L. Spadaro O. Magliocco D. Spampinato Omega-3 polyunsaturated fatty acids: a pilot trial in non-alcoholic fatty liver disease J Hepatol 44 2006 S264
102. L.C. Tapsell L.J. Gillen C.S. Patch Including walnuts in a low-fat/modified-fat diet improves HDL cholesterol-to-total cholesterol ratios in patients with type 2 diabetes Diabetes Care 27 2004 2777 2783
103. E. Lopez-Garcia M.B. Schulze J.B. Meigs Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction J Nutr 135 2005 562 566
104. D. Mozaffarian Trans fatty acids—effects on systemic inflammation and endothelial dysfunction Atheroscler Suppl 7 2006 29 32
105. S. Zelber-Sagi D. Nitzan-Kaluski R. Goldsmith Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study J Hepatol 47 2007 711 717
106. K.A. Le L. Tappy D.A. D'Alessio Mitochondrial dysfunction and insulin resistance: a matter of lifestyle? Curr Opin Nutr Metab Care 10 2007 494 497
107. K.B. Scribner D.B. Pawlak D.S. Ludwig Hepatic steatosis and increased adiposity in mice consuming rapidly versus slowly absorbed carbohydrate Obesity 15 2007 2190 2199
108. S.A. Harrison C.P. Day Benefits of lifestyle modification in NAFLD Gut 20 2007 29 43
109. A. Suzuki K. Lindor J. St Saver Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease J Hepatol 43 2005 1060 1066
110. T. Ueno H. Sugawara K. Sujaku Therapeutic effects of restricted diet and exercise in obese patients with fatty liver J Hepatol 27 1997 103 107
111. I.J. Hickman J.R. Jonsson J.B. Prins Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life Gut 53 2004 413 419
112. T.S. Church J.L. Kuk R. Ross Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease Gastroenterology 130 2006 2023 2030
113. S.A. Harrison C. Fincke D. Helinski A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients Aliment Pharmacol Ther 20 2004 623 628
114. N. Assy O. Hussein Z. Abassi Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis Gut 56 2007 443 444
115. S. Zelber-Sagi A. Kessler Brazowsky A double-blind randomized placebo controlled trial of orlistat for treatment of nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 4 2006 639 644
116. S.A. Harrison E.M. Brunt W.J. Fecht Orlistat in the treatment of overweight patients with nonalcoholic steatohepatitis (NASH): a multi-centered, randomized prospective trial Gastroenterology 132 2007 T1059
117. A.J. Scheen Cannabinoid-1 receptor antagonists in type-2 diabetes Best Pract Res Clin Endocrinol Metab 21 2007 535 553
118. M. Gary-Bobo G. Elachouri J.F. Gallas Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats Hepatology 46 2007 122 129
119. R.E. Amori J. Lau A.G. Pittas Efficacy and safety of incretin therapy in type 2 diabetes mellitus JAMA 298 2007 194 206
120. X. Ding N.K. Saxena S. Lin Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Hepatology 43 2006 173 181
121. M.E. Tushuizen M.C. Bunck P.J. Pouwels Incretin mimetics as a novel therapeutic option for hepatic steatosis Liver Int 26 2006 1015 1017
122. A.T. Marubbio H. Buchwald M.Z. Schwartz Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoileal bypass Am J Clin Pathol 66 1976 684 691
123. J.M. Campbell T.K. Hunt J.H. Karam Jejunoileal bypass as a treatment of morbid obesity Arch Intern Med 137 1976 602 610
124. S.G. Mattar L.M. Velcu M. Rabinovitz Surgically-induced weight loss significantly improved nonalcoholic fatty liver disease and the metabolic syndrome Ann Surg 242 2005 610 620
125. C.K. Furuya C.P. de Olivereira E.S. de Mello Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years J Gastroenterol Hepatol 22 2007 510 514
126. X. Liu A.J. Lazenby R.H. Clements Resolution of nonalcoholic steatohepatitis after gastric bypass surgery Obes Surg 17 2007 486 492
127. G. Lutchman K. Promrat D.E. Kleiner Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis, relationship to histologic improvement Clin Gastroenterol Hepatol 4 2006 1048 1052
128. B.A. Neuschwander-Tetri E.M. Brunt K.R. Wehmeier Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-y ligand rosiglitazone Hepatology 38 2003 1008 1017
129. V. Ratziu F. Charlotte S. Jacqueminet A one-year randomized, placebo-controlled, double-blind trial of rosiglitazone in non alcoholic steatohepatitis Results of the FLIRT pilot trial J Hepatol 44; 2006 A201
130. K. Promrat G. Lutchman G.I. Uwaifo A pilot study of pioglitazone for nonalcoholic steatohepatitis Hepatology 39 2004 188 196
131. A.J. Sanyal P.S. Mofrad M.J. Contos A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis Clin Gastroenterol Hepatol 2 2004 1107 1115
132. R. Belfort S.A. Harrison K. Brown A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 2006 15 25
133. G.P. Aithal J.A. Thomas P. Kaye A randomized, double blind, placebo controlled trial of one year of pioglitazone in non-diabetic subjects with nonalcoholic steatohepatitis Hepatology 46 2007 295A
134. G. Lutchman A. Modi D.E. Kleiner The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis Hepatology 46 2007 424 429
135. C.E. Murphy P.T. Rodgers Effects of thiazolidinediones on bone loss and fracture Ann Pharmacother 41 2007 2014 2018
136. S.E. Nissen K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
137. G. Diamond L. Bax S. Kaul Uncertain effects of rosiglitazone on the risk of myocardial infarction and cardiovascular death Ann Intern Med 147 2007 578 581
138. A.M. Lincoff K. Wolski S.J. Nicholls Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus A meta-analysis of randomized trials JAMA 298 2007 1180 1188
139. R.M. Lago P.P. Singh R.W. Nesto Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials Lancet 370 2007 1129 1136
140. H.Z. Lin S.Q. Yang C. Chuckaree Metformin reverses fatty liver disease in obese leptin-deficient mice Nat Med 6 2000 998 1003
141. G. Marchensini G. Bianchi S. Tomassetti Metformin in non-alcoholic steatohepatitis Lancet 348 2001 893 894
142. A. Uygun A. Kadayifci A.T. Isik Metformin in the treatment of patients with non-alcoholic steatohepatitis Aliment Pharmacol Ther 19 2004 537 544
143. S. Nair A.M. Diehl M. Wiseman Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial Aliment Pharmacol Ther 20 2004 23 28
144. E. Bugianesi E. Gentilcore R. Manini A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease Am J Gastroenterol 100 2005 1082 1090
145. M. Tiikkainen A.M. Hakkinen E. Korsheninnikova Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes Diabetes 53 2005 2169 2176
146. K. Mehta D.H. Van Thiel N. Shah Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants Nutr Rev 60 2002 289 293
147. S.A. Harrison S. Torgerson P. Hayashi Vitamin E and C treatment improves fibrosis in patients with nonalcoholic steatohepatitis Am J Gastroenterol 98 2003 2485 2490
148. F. Yakaryilmaz S. Guiliter B. Savas Effects of vitamin E treatment on peroxisome proliferators activated receptor-a expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study Intern Med J 37 2007 229 235
149. A. Federico M. Trappoliere C. Tuccillo A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations Gut 55 2006 901 902
150. M.F. Abdelmalek P. Angulo R. Jorgenssen Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study Am J Gastroenterol 96 2001 2711 2717
151. W.C. Houghton Betaine and nonalcoholic steatohepatitis Am J Gastroenterol 98 2003 2803
152. L. Valenti A.L. Fracanzani P. Dongiovanni Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study Am J Gastroenterol 102 2007 1251 1258
153. K.D. Lindor K.V. Kowdley E.J. Heathcote Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial Hepatology 39 2004 770 778
154. J.F. Dufour C.M. Oneta J.J. Gonvers Randomised placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis Clin Gastroenterol Hepatol 4 2006 1537 1543
155. L.A. Adams C.O. Zeine P. Angulo A pilot trial of pentoxifylline in nonalcoholic steatohepatitis Am J Gastroenterol 99 2004 2365 2368
156. S.K. Satapathy P. Sakhuja V. Malhotra Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis J Gastroenterol Hepatol 22 2006 634 638
157. J.D. Browning Statins and hepatic steatosis: perspectives from the Dallas heart study Hepatology 44 2006 466 471
158. M. Ekstedt L.E. Franzen U.L. Mathiesen Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study J Hepatol 47 2007 135 141
159. E. Gomez-Dominguez J.P. Gisbert J.A. Moreno-Monteagudo A pilot study of atorvastatin treatment in dyslipidemidic, non-alcoholic fatty liver patients Aliment Pharmacol Ther 23 2006 1643 1647
160. S. Devaraj D. Siegel I. Jialal Simvastatin (40mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome Am J Cardiol 100 2007 1397 1399
161. D.P. Mikhailidis G.C. Sibbring C.M. Ballantyne Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy Curr Med Res Opin 23 2007 2009 2026
162. M. Deushi M. Nomura A. Kawakami Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome FEBS Lett 581 2007 5664 5670
163. A. Hirose M. Ono T. Saibara Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis Hepatology 45 2007 1375 1381
164. S. Yokohama M. Yoneda M. Haneda Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis Hepatology 40 2004 1222 1225
165. S. Yokohama Y. Tokusashi K. Nakamura Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate activation in non-alcoholic steatohepatitis World J Gastroenterol 12 2006 322 326